Abstract
Purpose
Nelson’s syndrome (NS) is regarded as an aggressive complication of total bilateral adrenalectomy (TBA) for Cushing’s disease (CD). This challenge may be addressed by using clinical criteria to guide frequency of neuroimaging to enable timely management of NS and also avoid unnecessary frequent imaging.
Methods
All patients (n = 43) with CD subjected to TBA over 35 years at a tertiary care centre were included. NS was defined as a newly appearing or expanding (> 2 mm) pituitary adenoma with or without ACTH levels exceeding 500 pg/ml. Pre-and post-TBA parameters like clinical symptomatology, cortisol, ACTH and radiology were analysed for the prediction of NS.
Results
NS developed in 39.5% (n = 17) patients with a median follow-up of 7 years. Half of them had new appearance, while rest had an expansion of pre-existing pituitary tumour. Majority (90%) had ACTH above 500 pg/ml. On Cox proportional hazards analysis, frequent discriminatory features of protein catabolism (≥ 4) (HR 1.15, CI 0.18, 7.06), proximal myopathy (HR 8.82, CI 1.12, 69.58) and annual ACTH increment of 113 pg/ml (HR 12.56, CI 1.88, 88.76) predicted NS. First post-operative year ACTH indices predicting NS included ACTH rise of 116 pg/ml and absolute ACTH of 142 pg/ml (sensitivity, specificity exceeding 90%). Annual ACTH increment exceeding 113 pg/ml, ≥ 4 discriminatory features and uncontrolled hypertension had the best overall prediction.
Conclusion
Patients who developed NS had higher rebound rise of ACTH following TBA and a more severe disease phenotype at baseline. Consistent ACTH increment can be used as a marker for predicting the development of NS.
Similar content being viewed by others
Abbreviations
- NS:
-
Nelson’s syndrome
- CD:
-
Cushing’s disease
- CS:
-
Cushing’s syndrome
- TSS:
-
Trans-sphenoidal surgery
- TBA:
-
Total bilateral adrenalectomy
- ACTH:
-
Adrenocorticotropic hormone
- ONDST:
-
Overnight dexamethasone suppression test
- LDDST:
-
Low dose dexamethasone suppression test
- HDDST:
-
High dose dexamethasone suppression test
- IRMA:
-
Immunoradiometric assay
- ECLIA:
-
Electrochemiluminescence assay
- CV:
-
Coefficient of variation
- IQR:
-
Interquartile range
- SD:
-
Standard deviation
- UFC:
-
Urinary free cortisol
References
Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing's syndrome. Lancet 367:1605–1617
Petersenn S, Beckers A, Ferone D, van der Lely AJ, Bollerslev J, Boscaro M et al (2015) Outcomes in patients with Cushing’s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol 172(6):R227–R239
Reincke M, Ritzel K, Oßwald A, Berr C, Stalla G, Hallfeldt K, Reisch N, Schopohl J, Beuschlein F (2015) A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome. Eur J Endocrinol 173(4):M23–32
Guerin C, Taieb D, Treglia G, Brue T, Lacroix A, Sebag F, Castinetti F (2016) Bilateral adrenalectomy in the 21st century: when to use it for hypercortisolism? Endocr Relat Cancer 23(2):R131–R142
Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A (2015) Treatment of Cushing's syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol 100(8):2807–2831
Katznelson L (2015) Bilateral adrenalectomy for Cushing’s disease. Pituitary 18:269–273
Chow JT, Thompson GB, Grant CS, Farley DR, Richards ML, Young WF Jr (2008) Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing's syndrome: a review of the Mayo Clinic experience. Clin Endocrinol 68(4):513–519
Ritzel K, Beuschlein F, Mickisch A, Osswald A, Schneider HJ, Schopohl J, Reincke M (2013) Outcome of bilateral adrenalectomy in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab 98:3939–3948
Nelsons DH, Meakin JW, Dealy JB Jr, Matson DD, Emerson K Jr, Thorn GW (1958) ACTH-producing tumour of the pituitary gland. N Engl J Med 259:161–164
Barber TM, Adams E, Ansorge O, Byrne JV, Karavitaki N, Wass JA (2010) Nelson’s syndrome. Eur J Endocrinol 163:495–507
Assié G, Bahurel H, Coste J, Silvera S, Kujas M, Dugué MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X (2007) Corticotroph tumour progression after adrenalectomy in Cushing’s disease: a reappraisal of Nelson’s syndrome. J Clin Endocrinol Metab 92:172–179
Fountas A, Lim ES, Drake WM, Powlson AS, Gurnell M, Martin NM, Seejore K, Murray RD, MacFarlane J, Ahluwalia R, Swords F (2019) Outcomes of patients with Nelson’s syndrome after primary treatment: a multicenter study from 13 UK Pituitary centers. J Clin Endocrinol Metab. https://doi.org/10.1210/clinem/dgz200
Nagesser SK, van Seters AP, Kievit J, Hermans J, Krans HM, van de Velde CJ (2000) Long-term results of total adrenalectomy for Cushing's disease. World J Surg 24:108–113
Baranetsky NG, Zipser RD, Goebelsmann U, Robert RJ, March CM, Morimoto I, Stanczyk FZ (1979) Adrenocorticotropin-dependent virilizing paraovarian tumours in Nelson’s syndrome. J Clin Endocrinol Metab 49:381–386
Verdonk C, Guerin C, Lufkin E, Hodgson SF (1982) Activation of virilizing adrenal rest tissues by excessive ACTH production: an unusual presentation of Nelson’s syndrome. Am J Med 73:455–459
Carlstrom LP, Graffeo CS, Perry A, Stokken JK, Van Gompel JJ (2019) Nelson-Salassa syndrome progressing to pituitary carcinoma: a case report and review of the literature. Cureus 11(9):5595
Graffeo CS, Perry A, Carlstrom LP, Meyer FB, Atkinson JL, Erickson D, Nippoldt TB, Young WF, Pollock BE, Van Gompel JJ (2017) Characterizing and predicting the Nelson-Salassa syndrome. J Neurosurg 127:1277–1287
Kemink L, Pieters GF, Hermus AR, Smals A, Kloppenborg P (1994) Patient's age is a simple predictive factor for the development of Nelson’s syndrome after total adrenalectomy for Cushing's disease. J Clin Endocrinol Metab 79:887–889
Korbonits M, Bujalska I, Shimojo M, Nobes J, Jordan S, Grossman AB, Stewart PM (2001) Expression of 11β-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumours. J Clin Endocrinol Metab 86:2728–2733
Ar W, Odell Wd (1980) The dose-response relationship of ACTH and cortisol in Cushing's disease. Clin Endocrinol (Oxford) 12:557–568
Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. The Lancet 366:1059–1062
Misra A (2015) Ethnic-specific criteria for classification of body mass index: a perspective for Asian Indians and American Diabetes Association position statement. Diabet Technol Ther 17:667–671
American Diabetes Association (2020) Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. Diabetes Care 43(Supplement 1):S14–31
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ (2017ACC) 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71(19):e127–248
Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DS, Mechanick JI, Pessah-Pollack R (2017) American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract 23(s2):1–87
Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1526–1540
Verschraegen I, Anckaert E, Schiettecatte J, Mees M, Garrido A, Hermsen D et al (2007) Multicenter evaluation of a rapid electrochemiluminescent adrenocorticotropic hormone (ACTH) immunoassay. Clin Chim Acta 380:75–80
Raff H, Findling JW (1989) A new immunoradiometric assay for corticotropin evaluated in normal subjects and patients with Cushing's syndrome. Clin Chem 35:596–600
Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing's disease. Endocr Rev 36(4):385–486
Munir A, Newell-Price J (2007) Nelson's syndrome. Arquivos Brasileiros de Endocrinologia & Metabologia 51:1392–1396
Aron DC, Raff H, Findling JW (1997) Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing’s syndrome. J Clin Endocrinol Metab 82:1780–1785
Espinosa-de-Los-Monteros AL, Sosa-Eroza E, Espinosa E, Mendoza V, Arreola R, Mercado M (2017) Long-term outcome of the different treatment alternatives for recurrent and persistent Cushing disease. Endocr Pract 23:759–767
Pereira MA, Halpern A, Salgado LR, Mendonça BB, Nery M, Liberman B, Streeten DH, Wajchenberg BL (1998) A study of patients with Nelson’s syndrome. Clin Endocr (Oxford) 49:533–539
Sonino NI, Zielezny MA, Fava GA, Fallo F, Boscaro M (1996) Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab 81:2647–2652
Palermo NE, Ananthakrishnan S (2015) Re-examining Nelson's syndrome. Curr Opin Endocrinol Diabetes Obes 22(4):313–318
Assié G, Bahurel H, Bertherat J, Kujas M, Legmann P, Bertagna X (2004) The Nelson's syndrome revisited. Pituitary 7:209–215
Pérez-Rivas LG, Theodoropoulou M, Puar TH, Fazel J, Stieg MR, Ferraù F, Assié G, Gadelha MR, Deutschbein T, Fragoso MC, Kusters B (2018) Somatic USP8 mutations are frequent events in corticotroph tumour progression causing Nelson’s tumour. Eur J Endocrinol 178:57–63
Acknowledgements
We are highly indebted to late Prof Kanchan Kumar Mukherjee, who was instrumental in providing neurosurgical expertise as part of the treating team catering to these patients of Cushing’s disease at our centre. Unfortunately, he is no more with us but his legacy continues to live on.
Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Author information
Authors and Affiliations
Contributions
LD did data compilation and analysis, drafted the manuscript, edited it and reviewed the literature. AB edited the manuscript and supervised patient management. RP was involved in interpretation of data and editing the manuscript. PD edited the manuscript and supervised patient management. SKB supervised patient management. CA provided neuro-radiological expertise in terms of imaging interpretation and/or inferior petrosal sinus sampling. SK, RM and ARB did adrenal surgery. UNS performed histopathological analysis. SSD did pituitary surgery. RW conceived the study, managed the patients, collected the data, performed interpretation of data and statistical analysis and edited the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethical approval
Institutional ethics committee approval was obtained.
Consent to participate
Written informed consent for enrollment was obtained from participants or their relatives as applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Das, L., Bhansali, A., Pivonello, R. et al. ACTH increment post total bilateral adrenalectomy for Cushing’s disease: a consistent biosignature for predicting Nelson’s syndrome. Pituitary 23, 488–497 (2020). https://doi.org/10.1007/s11102-020-01047-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-020-01047-x